📊 NUVB Key Takeaways
Is Nuvation Bio Inc. (NUVB) a Good Investment?
Nuvation Bio is a pre-revenue pharmaceutical company with severe cash burn (-$173.4M operating cash flow) that will deplete its $164.1M cash position within 12 months without significant capital raises or revenue inflection. Despite modest revenue of $62.9M with flat YoY growth and a 20.7% gross margin, the company hemorrhages cash with -$325.3% net margin and -275.7% FCF margin, indicating an unsustainable business model with no clear path to profitability.
Balance sheet strength (current 6.95x, quick 6.81x) and low leverage provide meaningful runway while losses narrowed YoY. However, revenue is flat with low gross margin and operating/FCF remain deeply negative, keeping profitability distant and elevating financing risk if burn persists.
Why Buy Nuvation Bio Inc. Stock? NUVB Key Strengths
- Strong liquidity position with $164.1M cash and 6.95x current ratio providing runway for operations
- Low leverage with 0.15x debt-to-equity ratio limiting financial distress risk from debt obligations
- Positive gross margin of 20.7% demonstrates underlying product economics are viable at production level
- Strong liquidity (current 6.95x, quick 6.81x)
- Low leverage (0.15x D/E) with positive equity base
- Material YoY improvement in EPS and net loss
NUVB Stock Risks: Nuvation Bio Inc. Investment Risks
- Severe cash burn of $173.4M annually will exhaust cash reserves in approximately 12 months, forcing dilutive financing or operational shutdown
- Persistent operating losses of -$213.1M despite $62.9M revenue indicate R&D-heavy model with no near-term profitability pathway
- Flat revenue growth (0.0% YoY) combined with increasing net losses (-325.3% margin) shows deteriorating operational efficiency and failed commercialization
- Negative interest coverage of -21.0x indicates insufficient operating income to service debt obligations
- High insider trading activity (10 Form 4 filings in 90 days) may signal executive concern about company trajectory
- Sustained heavy cash burn and negative FCF (-$173.43M; -275.7% margin)
- Deeply negative margins and returns (operating, net, ROE/ROA)
- Financing/dilution risk given negative interest coverage and ongoing losses
Key Metrics to Watch
- Operating cash flow trend and months of cash runway remaining
- Revenue growth acceleration and gross margin sustainability
- Operating loss reduction rate and path to operating profitability
- Capital raise announcements and dilution impact on existing shareholders
- Pipeline milestone achievements and clinical trial progression
- Operating cash flow (TTM)
- Revenue growth (YoY)
Nuvation Bio Inc. (NUVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.95x current ratio provides a solid financial cushion.
NUVB Profit Margin, ROE & Profitability Analysis
NUVB vs Healthcare Sector: How Nuvation Bio Inc. Compares
How Nuvation Bio Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nuvation Bio Inc. Stock Overvalued? NUVB Valuation Analysis 2026
Based on fundamental analysis, Nuvation Bio Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nuvation Bio Inc. Balance Sheet: NUVB Debt, Cash & Liquidity
NUVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nuvation Bio Inc.'s revenue has grown significantly by 699% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.11 indicates the company is currently unprofitable.
NUVB Revenue Growth, EPS Growth & YoY Performance
NUVB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $727.0K | -$14.8M | $-0.15 |
| Q2 2025 | $1.4M | -$14.8M | $-0.17 |
| Q1 2025 | N/A | -$14.8M | $-0.07 |
| Q3 2024 | N/A | -$14.8M | $-0.09 |
| Q2 2024 | N/A | -$14.8M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nuvation Bio Inc. Dividends, Buybacks & Capital Allocation
NUVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nuvation Bio Inc. (CIK: 0001811063)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | DEF 14A | nuvb-20260521.htm | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080413.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010341.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010328.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010334.xml | View → |
❓ Frequently Asked Questions about NUVB
What is the AI rating for NUVB?
Nuvation Bio Inc. (NUVB) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUVB's key strengths?
Claude: Strong liquidity position with $164.1M cash and 6.95x current ratio providing runway for operations. Low leverage with 0.15x debt-to-equity ratio limiting financial distress risk from debt obligations. ChatGPT: Strong liquidity (current 6.95x, quick 6.81x). Low leverage (0.15x D/E) with positive equity base.
What are the risks of investing in NUVB?
Claude: Severe cash burn of $173.4M annually will exhaust cash reserves in approximately 12 months, forcing dilutive financing or operational shutdown. Persistent operating losses of -$213.1M despite $62.9M revenue indicate R&D-heavy model with no near-term profitability pathway. ChatGPT: Sustained heavy cash burn and negative FCF (-$173.43M; -275.7% margin). Deeply negative margins and returns (operating, net, ROE/ROA).
What is NUVB's revenue and growth?
Nuvation Bio Inc. reported revenue of $62.9M.
Does NUVB pay dividends?
Nuvation Bio Inc. does not currently pay dividends.
Where can I find NUVB SEC filings?
Official SEC filings for Nuvation Bio Inc. (CIK: 0001811063) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUVB's EPS?
Nuvation Bio Inc. has a diluted EPS of $-0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUVB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nuvation Bio Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUVB stock overvalued or undervalued?
Valuation metrics for NUVB: ROE of -66.9% (sector avg: 15%), net margin of -325.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUVB stock in 2026?
Our dual AI analysis gives Nuvation Bio Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUVB's free cash flow?
Nuvation Bio Inc.'s operating cash flow is $-173.4M, with capital expenditures of N/A. FCF margin is -275.7%.
How does NUVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -325.3% (avg: 12%), ROE -66.9% (avg: 15%), current ratio 6.95 (avg: 2).